Skip to main content
Fig. 1 | BMC Pharmacology and Toxicology

Fig. 1

From: A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

Fig. 1

MRD markers and donor chimerism in best responding patient. a/b MRD measurement via KMT2A/MLLT1 transcripts and IgH rearrangement in the best responding BPC-ALL patient revealed a response via SCT, but finally sustaining molecular response was reached via BEZ 235 treatment. c Donor chimerism in bone marrow was incomplete after allogeneic SCT with 1–5% autologous signal at day + 29 after SCT and dropping at early relapse. Soon after start of treatment with BEZ complete chimerism was reached

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us